Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
Across the post-pandemic launches, from those that entered in 2020, to those that launched in the third quarter of 2021 (and were then followed for their first six months of sales to Q1 2022) the average six-month sales remain down by 19% from the pre-pandemic benchmark. About the author. appeared first on.
59 
Let's personalize your content